FCGR3B

Across TCGA pan-cancer cohorts, FCGR3B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FCGR3B data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FCGR3B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FCGR3B expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where FCGR3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.211	0.670	.004	10	view →
PDAC	OS	Median	III,IV	0.739	0.328	.017	3	view →
GBM	OS	Median	All	0.178	0.743	.035	2	view →
HNSC	DFS	Tertile	III,IV	1.000	0.743	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FCGR3B–LUAD (OS)

Open the LUAD breakdown →